Regional efficacy and safety results of roxadustat compared with placebo or darbepoetin alfa in non–dialysis-dependent (NDD) chronic kidney disease (CKD) patients with anemia Ciro Esposito
11:12-11:24
SARS-CoV2 associated venous thromboembolism – a one-year follow-up
11:24-11:36
Efficacy and safety of ruxolitinib in primary/secondary myelofibrosis patients with co-morbidities and poli-pharmacy . Endri Mauro
11:36-11:48
A new score to predict a stroke mimic in a center with a high rate of thrombolysis Federico Moroni
11:48-12:00
The role of biomarkers in the prediction of short-time events in acute heart failure in a large population of elderly patients
12:00-12:12
Rapidly progressive paucimmune glomerulonephritis following COVID-19 infection
12:12-12:24
Ten-year efficacy and safety of azathioprine treatment in the maintainance of steroid-free remission in inflammatory bowel disease patients Claudio Cassieri
12:24-12:36
Indice di rischio e quoziente di normalizzazione: due nuovi indici per la valutazione della pressione arteriosa con ABPM. Studio su 4506 rapporti ABPM. Giovanni Malgieri
12:36-12:48
“Long COVID” features: incidence and risk factors
12:48-13:00
Efficacy, safety and appropriateness of the fixed-ratio combination (FRC) iGlarLixi in type 2 diabetes (T2D)
in real world settings: results from the ENSURE study Monica Larosa